Business
Market leadership in UK ENT market
Market leadership in UK ENT market.
About this update from Tristel Plc
[{"type":"text","content":"\n \nRNS Number : 4428P Tristel PLC 19 August 2014 \n \n\n \n \nTRISTEL plc\n(\"Tristel\", \"Group\" or the \"Company\")\n \nMarket leadership in UK Ear, Nose and Throat (\"ENT\") market\n \nTristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication in the British Journal of Nursing of an article titled \"Decontamination methods for flexible nasal endoscopes.\"\n \nThe authors, based at Gloucestershire Royal Hospital, Gloucester and Great Western Hospital, Swindon, conducted a national survey of current practice in the United Kingdom for the decontamination of flexible nasal endoscopes. Two hundred out-patient ENT departments were interviewed and the total number of respondents was 121, representing approximately one-fifth of the public and private hospital market. Of the respondents, 72 hospitals (60%) used the Tristel Wipes System and 13 hospitals (11%) used a Tristel liquid disinfectant. Tristel believes the outcome of the survey is representative of the entire UK hospital market.\n \nThe survey confirms that Tristel products, in particular the Tristel Wipes System, are the most commonly used decontamination method for nasal endoscopes in the UK ENT market.\n \nThe Company expects to report global sales of the Tristel Wipes System during the year ended 30 June 2014 of £6m, of which £3.8m in the UK. Other hospital departments in which this Tristel product is widely used include ultrasound and cardiology. \n \nPaul Swinney, Chief Executive Officer, comments: \"It has taken us a decade to establish this market leadership position in ENT. One of the great benefits of the Wipes System to a hospital is that it requires no capital investment and has no on-going maintenance cost. For a cash-strapped health system this is a tremendous advantage over the alternatives. As our three-part process is both unique and patented we have created a deeply entrenched position in this major clinical area.\"\n \n \n\n\n\n\nTristel plc\n\n\nwww.tristel.com\n\n\n\n\nPaul Swinney, Chief Executive \n\n\nTel: 01638 721 500\n\n\n\n\nLiz Dixon, Finance Director\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nfinnCap\n\n\n \n\n\n\n\nGeoff Nash / Charlotte Stranner, Corporate Finance\n\n\nTel: 020 7220 0500\n\n\n\n...